

# The Brazilian Journal of INFECTIOUS DISEASES

[www.elsevier.com/locate/bjid](http://www.elsevier.com/locate/bjid)



## Original article

# Therapy with radio-attenuated vaccine in experimental murine visceral leishmaniasis showed enhanced T cell and inducible nitric oxide synthase levels, suppressed tumor growth factor-beta production with higher expression of some signaling molecules



Sanchita Datta<sup>a</sup>, Syamal Roy<sup>b</sup>, Madhumita Manna<sup>a,\*</sup>

<sup>a</sup> Post Graduate Department of Zoology, Barasat Government College, Kolkata, India

<sup>b</sup> Infectious Diseases and Immunology, Indian Institute of Chemical Biology, Kolkata, India

## ARTICLE INFO

### Article history:

Received 7 May 2014

Accepted 6 October 2014

Available online 19 December 2014

### Keywords:

Radio-attenuated *Leishmania* parasites  
PDK1  
PI3K  
p38MAPK

## ABSTRACT

**Background:** Visceral leishmaniasis (VL) or Kala-Azar (KA) is one of the most deadly forms of disease among all neglected tropical diseases. There are no satisfactory drugs or vaccine candidates available for this dreaded disease. Our previous studies showed promising therapeutic and prophylactic efficacy of the live, radio-attenuated parasites through intramuscular (I.M.) and intraperitoneal (I.P.) route in BALB/c mice model.

**Methods:** The T-cell proliferation level, the mRNA expression level of inducible nitric oxide synthase (iNOS) and tumor growth factor-beta (TGF- $\beta$ ) genes and finally the phosphorylation levels of phosphoinositide dependent kinase 1 (PDK1), phosphoinositide 3 kinase (PI3K) and p38 mitogen activated protein kinase (p38MAPK) molecules were checked in BALB/c mice model immunized with radio-attenuated *Leishmania donovani* parasites through I.M. route. **Results:** Higher T-cell proliferation, increased iNOS level, and suppressed TGF- $\beta$  level were found in treated infected animal groups (100 and 150 Gy) in relation to untreated infected animals. Likewise, phosphorylation levels of PDK1, PI3K and p38MAPK of these two groups were increased when compared to untreated infected controls.

**Conclusion:** The clearance of the parasites from treated infected groups of animals may be mediated by the restoration of T-cell due to therapy with radio-attenuated *L. donovani* parasites. The killing of parasites was mediated by increase in nitric oxide release through PDK1, PI3K and p38MAPK signaling pathways. A lower TGF- $\beta$  expression has augmented the restored Th1 ambience in the 100 and 150 Gy treated animal groups proving further the efficacy of the candidate vaccine.

© 2015 Published by Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de [CC BY-NC-ND](https://creativecommons.org/licenses/by-nc-nd/4.0/)

\* Corresponding author at: Post Graduate Department of Zoology, Barasat Government College, 10 K.N.C. Road, Kolkata 700124, India.

E-mail address: [madhumita.manna09@gmail.com](mailto:madhumita.manna09@gmail.com) (M. Manna).

<http://dx.doi.org/10.1016/j.bjid.2014.10.009>

1413-8670/© 2015 Published by Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de [CC BY-NC-ND](https://creativecommons.org/licenses/by-nc-nd/4.0/)

## Introduction

Visceral leishmaniasis (VL) or Kala-Azar (KA) has been ranked second to malaria in terms of mortality and fourth for morbidity.<sup>1</sup> Global estimate is 50,000 new cases of VL each year and 90% of VL exist in Bangladesh, Brazil, India, Nepal and Sudan.<sup>2,3</sup> The inability of KA patients to mount an anti-leishmanial cell-mediated immune response is the hallmark of the disease.<sup>4</sup> The target pathogens are rapidly developing resistance against the available drugs including pentavalent antimonials.<sup>5</sup> Absence of any licensed vaccine for combating the disease is another serious problem in the control management program for VL worldwide. On the other hand, the observations that people cured from VL develop protection mediated by T helper 1 (Th1) type cellular responses against new infections<sup>6</sup> give impetus for the search of effective vaccine candidates. Invading *Leishmania* parasites are eliminated upon activation of macrophages by interferon-gamma (IFN- $\gamma$ ) secreted by Th1 cells and natural killer (NK) cells that empower them to destroy the intracellular *Leishmania* amastigotes by reactive nitric oxide (NO) mediated pathway.<sup>7</sup> Inhibition of nitric oxide production from inducible nitric oxide synthase (iNOS) by the parasites makes macrophages inactive to fight against the infection.<sup>8</sup> Any vaccine for leishmaniasis should trigger the Th1 pathway and suppress the T helper 2 (Th2) cytokines that exacerbate the disease. So far, many research groups have undertaken serious attempts in developing a successful vaccine against the disease which include use of live parasites,<sup>9</sup> killed parasites,<sup>10</sup> attenuated organisms,<sup>11-13</sup> recombinant protein vaccine,<sup>14</sup> DNA vaccines,<sup>15,16</sup> etc. Use of live non-attenuated parasites as vaccine candidate has not been recommended by WHO for a matter of safety as reversion of virulent forms would result in adverse side effects including immunosuppression.<sup>17</sup> *Leishmania* parasites without virulence factor, yet maintaining the immunogenic attributes, is of great interest as attenuated parasites closely mimic the natural infection that may lead to similar immune responses without the fear of infection with live virulent parasites.<sup>18</sup> Ionizing radiation has long been used to attenuate parasites for the purpose of vaccine development.<sup>19-24</sup> Irradiation often causes loss or reduction of virulence and reproductive ability of the pathogens but retains their metabolic activities, morphology and antigenic profile. Thus, radio-attenuated parasites are able to trigger specific immune responses without posing risk of progressive infection.<sup>25</sup> More interestingly, in some cases, the radio-attenuated pathogens are more immunogenic than the normal counterparts.<sup>26</sup> Use of radio-attenuated *Leishmania* parasites is in practice for quite a long time now.<sup>22,27,28</sup> Previously our group had checked the prophylactic and therapeutic efficacy of the irradiated *Leishmania donovani* parasites in experimental murine model and got encouraging results.<sup>29-31</sup> The present study is an extension of earlier works to see whether there is any restoration from T cell energy, induction of inducible iNOS and suppression of Th 2 arm of immune response by studying T cell proliferation, iNOS gene, and TGF- $\beta$  gene expression, respectively. It is also an initial attempt to understand the underlying mechanism of parasite clearance by macrophages following the expressions of some signaling molecules like

phosphoinositide 3 kinase (PI3K), phosphoinositide-dependent kinase 1 (PDK1) and p38 mitogen-activated protein kinase (p38MAPK), respectively, in the groups of animals receiving therapy with attenuated homologous vaccine through I.M. route.

## Materials and methods

### Reagents

HEPES, penicillin, streptomycin, sodium bicarbonate, 2-mercaptoethanol (2-ME), bovine serum albumin (BSA), histopaque, fetal calf serum (FCS), RPMI 1640 medium, M 199 medium were purchased from Sigma-Aldrich. Anti-PI3K and anti-phospho-PI3K (p85) were obtained from Santa Cruz Biotech, Inc. All other antibodies [anti-phosphoinositide-dependent kinase 1 (PDK1) and anti-phospho-PDK1, anti-p38 mitogen-activated protein kinase (p38MAPK) and anti-phospho-P38MAPK] and LumiGlo reagents for chemiluminescence were obtained from Cell Signaling (Beverly, MA). Tritiated thymidine [<sup>3</sup>H]-thymidine (6.7 Ci/mmol) was obtained from PerkinElmer®, deoxynucleoside triphosphates obtained from Promega, Taq polymerase and Moloney leukemia virus reverse transcriptase were purchased from Invitrogen and RNeasy minikit was purchased from Qiagen.

### Animals, parasites and infection

BALB/c mice 4-6 weeks old with almost equal weight and same sex, reared in Institute facilities, were used for experimental purposes with prior approval of the Animal Ethics Committee of the Indian Institute of Chemical Biology, Kolkata and all animal experimentations were performed at Indian Institute of Chemical Biology, Kolkata, India following the National Regulatory Guidelines issued by Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Ministry of Environment and Forest, Govt. of India. *L. donovani* isolate, AG83 (MHOM/IN/1983/AG83), originally obtained from confirmed an Indian Kala-Azar patient was used for the preparation of the live-attenuated vaccine candidate. This isolate is maintained in Golden hamsters and the promastigotes obtained after transforming the amastigotes from infected animal spleen were cultured in medium M 199 supplemented with 10% FCS along with 100 U/ml penicillin and 100  $\mu$ g/ml streptomycin, maintained at 22 °C.<sup>32</sup>

### Therapy with attenuated parasites

*L. donovani* isolate, AG83, was attenuated by gamma irradiation from a <sup>60</sup>Co gamma chamber with a rate of radiation of 10 Gy/60 s at Indian Institute of Chemical Biology, Kolkata, India. AG83 parasites ( $5 \times 10^6$ /BALB/c mice) were irradiated and washed three times in sterile phosphate buffer saline (PBS) and irradiated in the gamma chamber at three different doses: 50, 100, and 150 Gy respectively. The description of the animal groups for the study was as follows: Group 1, normal control animals without any infection and therapeutic immunization; Group 2, infected control animals without any immunization, while Group 3, Group 4 and Group 5 were

animals that had been infected and received therapeutic immunizations with *L. donovani* isolate, AG83 ( $5 \times 10^6$  parasites/animal) attenuated at 50, 100 and 150 Gy doses of gamma radiation, respectively, at 75 days post-infection. The treatment was repeated for three immunized groups at 15-day interval. The mice were sacrificed 15 days after the last treatment, for experimental purposes.

### T-cell proliferation assay

T-cell proliferation assay was performed as described previously.<sup>33</sup> Briefly, single cell suspensions of splenocytes from different experimental groups of BALB/c mice were prepared after Ficoll density gradient centrifugation and then suspended in complete RPMI 1640. Cells were plated in triplicate at  $10^5$  cell/well concentrations in 96-well plates and allowed to proliferate for 72 h at 37 °C in 5% CO<sub>2</sub> incubator in the presence of SLA concentration (5 µg/ml). Eighteen hours before they were harvested in GFC membrane, cells were pulsed with 1 µCi [<sup>3</sup>H]-thymidine/well. [<sup>3</sup>H]-Thymidine incorporation was measured by liquid scintillation counter (Tri-Carb 2100TR; Packard Instrument).

### RNA isolation and semi-quantitative RT-PCR analyses of TGF-β and iNOS genes

RNA isolation from the splenocytes was performed using the RNeasy minikit procedure (Qiagen).<sup>15</sup> Forward and reverse primers were used to amplify the transcripts. Samples (1 µg) of RNA from different experimental groups of mice were first utilized for cDNA synthesis with reverse primers (IDT; Sigma) using Mouse Moloney Leukemia Virus reverse transcriptase (Invitrogen) at 37 °C for 90 min. A common master mixture containing deoxynucleoside triphosphates (Promega) and Taq polymerase (Invitrogen), as well as gene specific primers and 0.25 volume of cDNA, was used for amplification with an Applied Biosystems thermocycler. The cycling conditions for genes of interest were 5 min at 95 °C, followed by 40 cycles of denaturation at 95 °C for 30 s, annealing at 56 °C for 40 s, and extension at 72 °C for 40 s. The identities of the PCR amplified gene products were verified by agarose gel electrophoresis. Identical aliquots were processed in parallel without reverse transcriptase to rule out the presence of residual genomic DNA contamination in PCR amplification preparations. Densitometric analyses were done using the Quantity One software (Bio-Rad), ethidium bromide staining, and visualization under a UV transilluminator. For densitometric calculations, the same band area was used to determine band intensity and normalized for HGPRT.

### Western blot analysis

Splenocytes from different groups of animals were harvested, resuspended in chilled lysis buffer (containing 20 mM Tris-HCl (pH 7.5), 0.5 mM EGTA, 1 mM EDTA, 0.1% (vol/vol) 2-mercaptoethanol)<sup>34</sup> and rapidly freeze-thawed thrice and passed through a 26-gauge needle (10 times) for lysis. The lysates were centrifuged ( $800 \times g$  for 10 min at 4 °C), the supernatants were collected, and the proteins were estimated using Bradford reagent. The supernatants were mixed

with Laemmli buffer, heated in a boiling water bath for five min and cooled to room temperature. About 20 µg of protein was loaded in lanes of Sodium Dodecyl Sulfate Poly Acrylamide Gels (SDS-PAGE) for electrophoresis. After the run, the gel was transferred to polyvinylidene difluoride membrane. Immunoblotting was performed with appropriately diluted specific primary antibodies for PI3K (anti-phosphoinositide 3 kinase Mab) and phospho PDK1 (anti-phosphoinositide-dependent Kinase 1 Mab) and p38MAPK (anti-p38 mitogen-activated protein kinase Mab) respectively. Finally, chemiluminescence was performed with LumiGlo reagent as described by the manufacturer.<sup>35</sup> Densitometry analyses were done using Quantity1 (Bio-Rad) software.<sup>15</sup>

### Statistical analysis

Each experiment was performed three times and results are expressed as means ± SD. Student's t-test was performed for significance and a *p*-value of <0.05 was considered significant. Western blots and RT-PCR show representative data from three independent experiments. \* *p* < 0.05, \*\* *p* < 0.01, \*\*\* *p* < 0.001.

## Results

### Reversal of T cell responsiveness after therapy with radio attenuated parasites


Cell mediated immunity is impaired in *Leishmania* infection characterized by marked T cell anergy to specific *Leishmania* antigens.<sup>15</sup> After observing the potential therapeutic effects of 100 and 150 Gy attenuated parasites in terms of reduction in organ parasite burden,<sup>31</sup> we became interested to see whether the T cell anergy observed during progressive infection could be reversed by the treatment. Splenocytes of infected animals (Group 2) failed to mount anti-leishmanial T cell proliferation to leishmanial antigens suggesting global immune unresponsiveness at the active stage of the disease. Though Group 3 animals were treated with 50 Gy radio-attenuated parasites, they also failed to do so. On the other hand, the splenocytes from treated groups (Group 4 and Group 5) stimulated with SLA showed a significantly (*p* < 0.001) higher level (3.5–4 folds) of T cell proliferation (Fig. 1).

### Expressions of iNOS and TGF-β genes

The mRNA expression levels of iNOS and TGF-β genes (Fig. 2) were checked in different animal groups by RT-PCR method. A significantly higher level of expression (six-fold, *p* < 0.001) of iNOS mRNA was seen in animals of groups 4 and 5, whereas expression of TGF-β mRNA has been lowered by two-fold (*p* < 0.001) in the same groups of animals compared to that of infected group of animals (Group 2). Treated animals of Group 3 did not show such increment or decrement.

### Western blot analyses for PI3K, PDK1 and p38MAPK

In order to score the changes, if any, in the signaling mechanisms of splenocytes of the immunized animals, immunoblot studies were carried out with PI3K, PDK1, and P38MAPK



N, Normal; I, Infected; Gy, Gray; CPM, Count per minute; \*,  $P < .05$ , \*\*,  $P < .01$ , \*\*\*,  $P < .001$ .

**Fig. 1 – T cell proliferation assay in BALB/c mice groups. Number of proliferated T cells is expressed as CPM (count per minute). Proliferations of T cells were checked and compared between infected control group and treated animal groups (50, 100 and 150 Gy groups), respectively. Higher T-cell proliferations compared to infected animals were found in the treated animal groups, 100 and 150 Gy, respectively. Left to right, bars represent N, healthy control; I, Infected: mice received infection only; 50, 100, 150 Gy represent three groups of mice treated with attenuated *Leishmania donovani* parasites, doses of attenuation being 50, 100 and 150 Gy absorbed doses of  $\gamma$ -radiation, respectively. Infected ( $5 \times 10^6$  parasites/animal) and treated (twice @  $5 \times 10^6$  parasites per animal in 15-day interval) mice were sacrificed at 120 dpi. Splenocytes were isolated and cultured in medium RPMI-1640 in 24-well plates @  $2 \times 10^6$  splenocytes/well. After 72 h the splenocytes were pulsed with  $H^3$  thymidine and after 18 h of pulsing the count was taken in liquid scintillation counter. Data represent mean  $\pm$  SD of six animals per group and are representative of three independent experiments; paired two-tailed Student's t-test was performed.  $p < 0.05$  was considered significant.**


molecules (Fig. 3). These are some of the most important molecules in triggering the production of free radicals like NO and ROS. In our previous intramuscular therapeutic studies, we identified a significant increase of nitric oxide (NO) and reactive oxygen species (ROS) levels in animals of different immunized/treated groups.<sup>30,31</sup> We measured the phosphorylation level of these three molecules in splenocytes of the animals and observed from 3.5- to 4-fold increase in phosphorylation in 100 and 150 Gy animal groups compared to the infected groups (Fig. 3). This indicates the participation of these molecules in activating the effector molecules so that protection could be achieved. Animals of Group 3 that received immunization with parasites attenuated with 50 Gy dose of radiation did not show any higher expression in terms of phosphorylation of any of the three signaling proteins studied here. This corroborates our previous observations where we noticed that this group of animals had no protection and succumbed to the disease.<sup>30,31</sup>

## Discussion

We saw that attenuated parasites activated the microbicidal mechanisms of macrophages in the model host body and then the activated macrophages efficiently cleared intracellular parasites from spleen and liver cells of the protected animal groups. In our therapeutic study,<sup>31</sup> the increased release of IFN- $\gamma$  (three-fold higher than the infected group of animals) from the infected and then treated groups (100 and 150 Gy) supported our hypothesis that the Th2 ambience already created in infected conditions has been overrode by the Th1 atmosphere generated by therapeutic use of radio-attenuated *L. donovani*. While in case of our prophylactic study,<sup>30</sup> the radio-attenuated *L. donovani* parasites generated an active Th1 ambience inside the immunized host body before the host was exposed to virulent *L. donovani* parasites which did not allow the disease progress. The primed and then challenged groups of mice showed IFN- $\gamma$  release 15-fold higher than Interleukin 4 (IL-4) and about five-fold higher than IL-10.<sup>30</sup> Mechanistically thus both approaches are dependent either on the presence or on the establishment of Th1 milieu. Attainment of the right doses of attenuation is still a difficult task as it is directly related to the efficacy of the vaccine in one hand and to safety issues in another. If the dose of attenuation by gamma radiation is too low, there is a chance of reversion to virulent form of the pathogens causing disease progression undermining the purpose. If the dose of attenuation by gamma radiation is too high, it will immediately kill the parasites; thus, host immune response will not be evoked as live promastigotes have the potential to induce various cells to produce IFN- $\gamma$ , a property which dead promastigotes lacked.<sup>36</sup> Manna et al.<sup>37</sup> reported that the limiting dose of attenuation by gamma radiation for *L. donovani* parasites is 20 Krad (200 Gy) up to which cells can employ homeoviscous adaptation to survive and compensate the altered conditions. In our own experiences from prophylactic and therapeutic studies, we have seen that 100 and 150 Gy were the right doses of attenuation to evoke immune response in experimental hosts while 50 Gy may cause reversion as evidenced from survival kinetics and parasite burden analyses of spleen and liver cells of 50 Gy treated animals. Thus, extreme caution must be taken to select the right doses of attenuation.

Our previous studies had shown that BALB/c mice treated with 100 and 150 Gy radio-attenuated parasites through I.M. route (and also through I.P. route) have much lower parasite burden and less hepato and splenomegaly compared to unimmunized infected animals. A significant increase in levels of free radicals, an increased Th1 cytokines profile and decreased Th2 levels in these animals compared with the infected animal groups indicated the successful clearance of intracellular parasites in these two groups, but not in 50 Gy irradiated group.<sup>6</sup> Both ROS and NO are known to be involved in parasite killing in the early stage of *Leishmania* infection in mice and NO alone is involved in the late phase of infection.<sup>38</sup> ROS generation is reported to involve molecules like PI3K,<sup>39</sup> PKC,<sup>40</sup> ERK and Ras.<sup>38,41</sup> P38 MAPK has been reported to be involved in the generation of NO<sup>42</sup> while activation of P38 MAPK is dependent upon PI3K activation.<sup>43</sup> Among other associated molecules, PDK1 is an intermediate molecule in the P38MAPK






**Fig. 2** – RT-PCR in BALB/c mice groups for checking the expressions of iNOS and TGF-β genes. Levels of iNOS and TGF-β genes expression were compared between infected control group and treated animal groups (50, 100 and 150 Gy groups), respectively. Left to right, bands and bars represent 1, healthy control; 2, Infected: mice received infection only; 3, 4, 5 represent three groups of mice treated with attenuated *Leishmania donovani* parasites, doses of attenuation being 50, 100 and 150 Gy absorbed doses of  $\gamma$ -radiation, respectively. Infected ( $5 \times 10^6$  parasites/animal) and treated (twice @  $5 \times 10^6$  parasites per animal in 15 days interval) mice were sacrificed at 120 dpi. Splenocytes were isolated from which RNA was prepared. cDNA was prepared from RNA and PCR experiments were carried out for iNOS and TGF-β gene expressions taking HGPRT gene as the housekeeping gene for internal control. Densitometry analysis was done and the ratio of iNOS and TGF-β expressed in the bar diagram. All data were compared to the infected control group. Data represent mean  $\pm$  SD of six animals per group and are representative of three independent experiments; paired two-tailed Student's t-test was performed.  $p < 0.05$  was considered significant. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ .

activation pathway,<sup>44</sup> and P38MAPK is well known to trigger the production of TNF- $\alpha$  which induces iNOS expression and NO generation.<sup>45</sup> In our prophylactic study, we observed 3.5- to

3.9-fold higher TNF- $\alpha$  releases in 100 and 150 Gy groups.<sup>30</sup> In the present study, the expression of iNOS was observed to be six-fold higher in the same treatment groups. TGF-β causes



**Fig. 3** – Western blot analysis to evaluate PDK1, PI3K and p38MAPK phosphorylation levels in BALB/C mice groups. Levels of PDK1, PI3K and p38MAPK phosphorylation were checked and compared between infected control group and treated animal groups (50, 100 and 150 Gy groups), respectively. Splenocytes from different groups of animals were taken and the cell lysates were prepared and run in 10% polyacrylamide gels and then immunoblotted with respective monoclonal antibodies (MAbs) against non-phosphorylated and phosphorylated forms with  $\beta$  actin as an internal control. Phosphorylation status of each of the above mentioned molecules were expressed as the densitometric ratio of the phosphorylated form (labeled phospho or P) versus the internal control ( $\beta$ -actin). Left to right, bars represent N, healthy control; I, infected: mice received infection only; 50, 100, 150 Gy represent three groups of mice treated with attenuated *Leishmania donovani* parasites, doses of attenuation being 50, 100 and 150 Gy absorbed doses of  $\gamma$ -radiation, respectively. Infected ( $5 \times 10^6$  parasites/animal) and treated (twice @  $5 \times 10^6$  parasites per animal in 15 days interval) mice were sacrificed at 75 dpi. Splenocytes were isolated and cultured in medium RPMI-1640 in 24-well plates @  $2 \times 10^6$  splenocytes/well. Representative data of three similar experiments are presented here. Data represent mean  $\pm$  SD value of three repeat experiments with six animals in each group; paired two-tailed Student's t-test was performed.  $p < 0.05$  was considered significant. \*,  $p < 0.05$ ; \*\*,  $p < 0.01$ ; \*\*\*,  $p < 0.001$ .

the transcription of mRNA involved in immune suppression, the hall mark of full blown KA state.<sup>35</sup> This Th2 cytokine gene expression is significantly reduced (two-fold,  $p < 0.001$ ) in these two groups suggesting that restoration of Th1 ambience has been initiated and established after successful therapy with radio-attenuated parasites. The 100 and 150 Gy treated animals also showed a significant increase in PI3K phosphorylation, which in turn activates PDK1 phosphorylation. These are in congruence with observations by other workers.<sup>46</sup> After activation, PDK1 could activate different PKC isotypes, which are responsible for the phosphorylation of ERK molecules that ultimately trigger ROS generation. Activated PI3K also activates P38 MAPK phosphorylation through Akt activation<sup>43</sup> leading to NO production. In this preliminary study, we have also noticed higher level of p38 MAPK phosphorylation, which could increase TNF- $\alpha$  production<sup>45</sup> and in turn induces NOS2 expression and subsequent NO generation.<sup>45</sup>

The results of the present study showed that radio-attenuated live vaccine may help the animals to recover from T cell anergy, induce NOS2 and suppress TGF- $\beta$  gene expression. The NO and ROS induced parasite killing by macrophages, in groups of animals treated with radio-attenuated homologous vaccine, may follow PI3K-p38MAPK mediated NO generation in one hand and the PI3K-PDK1 mediated ROS generation on the other. Further studies are in progress.

### Conflicts of interest

The authors declare no conflicts of interest.

### Acknowledgements

The authors are thankful to the Council for Scientific and Industrial Research (CSIR), India for the fellowship of Sanchita Datta, CSIR Senior Research Fellow [sanction no. ACK No. 112449/2K10/1 dt 29.03.11]. The authors acknowledge the help of the Director, Public Instructions, Government of West Bengal, India and the Principal, Barasat Govt. College, Kolkata. The kind cooperation of the Director, Indian Institute of Chemical Biology, Kolkata, India is duly acknowledged.

### REFERENCES

- Mathers CD, Ezzati M, Lopez AD. Measuring the burden of neglected tropical diseases: the global burden of disease framework. *PLoS Negl Trop Dis*. 2007;1:114.
- Desjeux P. Leishmaniasis: current situation and new perspectives. *Comp Immunol Microbiol Infect Dis*. 2004;27:305-18.
- Sundar S. Drug resistances in Indian visceral leishmaniasis. *Trop Med Int Health*. 2001;6:849-54.
- Svensson M, Maroof A, Ato M, Kaye PM. Stromal cells direct local differentiation of regulatory dendritic cells. *Immunity*. 2004;21:805-16.
- Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. *Clin Microbiol Rev*. 2006;19:111-26.
- Kumar R, Goto Y, Gidwani K, Cowgill KD, Sundar S, Reed SG. Evaluation of *ex vivo* human immune response against candidate antigens for a visceral leishmaniasis vaccine. *Am J Trop Med Hyg*. 2010;82:808-13.
- Stenger S, Rollinghoff M. Role of cytokines in the innate immune response to intracellular pathogens. *Ann Rheum Dis*. 2001;60:43-6.
- Bogdan C, Rollinghoff M. How do protozoan parasites survive inside macrophages? *Parasitol Today*. 1999;15:22-8.
- Titus RG, Frederico J, Gueiros F, Freitas LA, Beverley SM. Development of a safe live *Leishmania* vaccine line by gene replacement. *Proc Natl Acad Sci U S A*. 1995;92:10267-71.
- Okwor I, Liu D, Beverley SM, Uzonna JE. Inoculation of killed *Leishmania major* into immune mice rapidly disrupts immunity to a secondary challenge via IL-10-mediated process. *Proc Natl Acad Sci U S A*. 2009;33:13951-6.
- Rivier D, Shah R, Bovay P, Mauel J. Vaccine development against cutaneous leishmaniasis: subcutaneous administration of radioattenuated parasites protects CBA mice against virulent *Leishmania major* challenge. *Parasite Immunol*. 1993;15:75-84.
- Handman E. *Leishmania* vaccines: old and new. *Parasitol Today*. 1997;13:236-8.
- Mukhopadhyay S, Bhattacharyya S, Majhi R, et al. Use of an attenuated *Leishmanial* parasite as an immunoprophylactic and immunotherapeutic agent against murine visceral leishmaniasis. *Clin Diagn Lab Immunol*. 2000;7:233-40.
- Peters NC, Bertholet S, Lawyer PG, et al. Evaluation of recombinant *Leishmania* polyprotein plus glucopyranosyl lipid A stable emulsion vaccines against sand fly transmitted *Leishmania major* in C57BL/6 mice. *J Immunol*. 2012;189:4832-41.
- Basu R, Bhaumik S, Haldar AK, et al. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of *Leishmania donovani* that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. *J Immunol*. 2005;174:7160-71.
- Guha R, Gupta D, Rastogi R, et al. Vaccination with *Leishmania* hemoglobin receptor-encoding DNA protects against visceral leishmaniasis. *Sci Transl Med*. 2013;5:202-21.
- Reithinger R, Dujardin J, Louzir H, et al. Cutaneous leishmaniasis. *Lancet Infect Dis*. 2007;7:581-96.
- Handman E. Leishmaniasis: current status of vaccine development. *Clin Microbiol Rev*. 2001;14:229-43.
- Coulson PS. The radiation-attenuated vaccine against schistosomes in animal models: paradigm for a human vaccine. *Adv Parasitol*. 1997;39:271-336.
- Hiramoto RM, Galisteo AJ Jr, Nascimento N, Andrade HF Jr. 200 Gy sterilised *Toxoplasma gondii* tachyzoites maintain metabolic functions and mammalian cell invasion, eliciting cellular immunity and cytokine response similar to natural infection in mice. *Vaccine*. 2002;20:2072-81.
- Scheller LF, Azad AF. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. *Proc Natl Acad Sci U S A*. 1995;92:4066-8.
- Rivier D, Shah R, Bovay P, Mauel J. Vaccine development against cutaneous leishmaniasis. Subcutaneous administration of radioattenuated parasites protects CBA mice against virulent *Leishmania major* challenge. *Parasite Immunol*. 1993;15:75-84.
- Yoshimoto T, Yoneto T, Waki S, Nariuchi H. Interleukin-12-dependent mechanisms in the clearance of blood-stage murine malaria parasite *Plasmodium berghei* XAT, an attenuated variant of *P. berghei* NK65. *J Infect Dis*. 1998;177:1674-81.
- Jenkins MC, Chute MB, Danforth HD. Protection against coccidiosis in outbreak chickens elicited by gamma irradiated *Eimeria maxima*. *Avian Dis*. 1997;41:702-8.

25. Demicheli MC, Reis BS, Goes AM, de Andrade AS. *Paracoccidioides brasiliensis*: attenuation of yeast cells by gamma irradiation. *Mycoses*. 2006;49:184-9.
26. Wales A, Kusel JR. Biochemistry of irradiated parasite vaccines: suggested models for their mode of action. *Parasitol Today*. 1992;8:358-63.
27. Alexander J. A radioattenuated *Leishmania major* vaccine markedly increases the resistance of CBA mice to subsequent infection with *Leishmania mexicana*. *Trans R Soc Trop Med Hyg*. 1982;76:646-9.
28. Lemma A, Cole L. *Leishmania enrietti*: radiation effects and evaluation of radioattenuated organisms for vaccination. *Exp Parasitol*. 1974;35:161-9.
29. Datta S, Naskar K, Chakraborty A, Manna M. Immunotherapeutic role of radio attenuated *Leishmania* parasites in experimental murine leishmaniasis. In: XIIth international congress on parasitology. Melbourne, Australia: Medimond International Proceedings; 2010 [No. M815S7113].
30. Datta S, Adak R, Chakraborty P, et al. Radio-attenuated leishmanial parasites as immunoprophylactic agent against experimental murine visceral leishmaniasis. *Exp Parasitol*. 2011;130:39-47.
31. Datta S, Manna M, Khanra S, et al. Therapeutic immunization with radio-attenuated *Leishmania* parasites through i.m. route revealed protection against the experimental murine visceral leishmaniasis. *Parasitol Res*. 2012;111:361-9.
32. Mukhopadhyay S, Sen P, Bhattacharyya S, Majumdar S, Roy S. Immunoprophylaxis and immunotherapy against experimental visceral leishmaniasis. *Vaccine*. 1999;17:291-300.
33. Roy S, Scherer MT, Briner TJ, Smith JA, Geffer ML. Murine MHC polymorphism and T cell specificities. *Science*. 1989;244:572-5.
34. Mookerjee A, Sen PC, Ghose AC. Immunosuppression in hamsters with progressive visceral leishmaniasis is associated with an impairment of protein kinase C activity in their lymphocytes that can be partially reversed by okadaic acid or anti-transforming growth factor  $\beta$  antibody. *Infect Immun*. 2003;71:2439-46.
35. Mookerjee Basu J, Mookerjee A, Sen P, et al. Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in *Leishmania donovani*-infected macrophages. *Antimicrob Agents Chemother*. 2006;50:1788-97.
36. Nylén S, Maasho K, Soderstrom K, Ilg T, Akuffo H. Live *Leishmania* promastigotes can directly activate primary human natural killer cells to produce interferon-gamma. *Clin Exp Immunol*. 2003;131:457-67.
37. Manna S, Chakravarty R, Manna B, Bhattacharya A. Radiation induced alterations in membrane fluidity, microtubular structure, glycoconjugates and protein in *Leishmania donovani*. *Res J Parasitol*. 2006;1:48-58.
38. Murray HW, Nathan CF. Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral *Leishmania donovani*. *J Exp Med*. 1999;189:741-6.
39. Dreiem A, Myhre O, Fonnum F. Involvement of the extracellular signal regulated kinase pathway in hydrocarbon-induced reactive oxygen species formation in human neutrophil granulocytes. *Toxicol Appl Pharmacol*. 2003;190:102-10.
40. Vladimirova O, Lu FM, Shawver L, Kalman B. The activation of protein kinase C induces higher production of reactive oxygen species by mononuclear cells in patients with multiple sclerosis than in controls. *Inflamm Res*. 1999;48:412-6.
41. Seru R, Mondola P, Damiano S, et al. Ras activates the NADPH oxidase complex in human neuroblastoma cells via extracellular signal-regulated kinase 1/2 pathway. *J Neurochem*. 2004;91:613-22.
42. Amer AO, Swanson MS. Phagosome of one's own: a microbial guide to life in the macrophage. *Curr Opin Microbiol*. 2002;5:56-61.
43. Kao SJ, Lei HC, Kuo CT, et al. Lipoteichoic acid induces nuclear factor-kappaB activation and nitric oxide synthase expression via phosphatidylinositol 3-kinase, Akt, and p38 MAPK in RAW 264.7 macrophages. *Immunology*. 2006;115:366-74.
44. Lee HM, Jin HS, Park JW, et al. IL-4 augments anisomycin-induced p38 activation via Akt pathway in a follicular dendritic cell (FDC)-like line. *FEBS Lett*. 2003;549:110-4.
45. Li Y, Schwabe RF, DeVries-Seimon T, et al. Free cholesterol-loaded macrophages are an abundant source of tumor necrosis factor-alpha and interleukin-6: model of NF-kappa B and MAP kinase-dependent inflammation in advanced atherosclerosis. *J Biol Chem*. 2005;280:21763-72.
46. Cantrell DA. Phosphoinositide 3-kinase signalling pathways. *J Cell Sci*. 2001;114:1439-45.